CN1558765A - 对映异构体纯的阿片样物质二芳基甲基哌嗪及其使用方法 - Google Patents
对映异构体纯的阿片样物质二芳基甲基哌嗪及其使用方法 Download PDFInfo
- Publication number
- CN1558765A CN1558765A CNA028187806A CN02818780A CN1558765A CN 1558765 A CN1558765 A CN 1558765A CN A028187806 A CNA028187806 A CN A028187806A CN 02818780 A CN02818780 A CN 02818780A CN 1558765 A CN1558765 A CN 1558765A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- receptor
- respiration inhibition
- animal
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
化合物# | 类型 | 大鼠脑膜Ki(nM) | 豚鼠脑膜Ki(nM) | |
μ | δ | κ | ||
1 | 外消旋混合物DPI-1197W92(RRS和SSR) | 0.36 | 1.29 | 1.67 |
2 | 对映异构体DPI-125(SSR) | 0.40 | 0.88 | 1.77 |
3 | 对映异构体DPI-165(RRS) | 658 | 744 | 100 |
4 | 外消旋混合物DPI-1198W92(RSR和SRS) | 0.18 | 14.9 | 2.34 |
5 | 对映异构体ARD-444(RSR) | 0.75 | 113 | 1.73 |
6 | 对映异构体DPI-3553W92(SRS) | 60 | 13 | 16 |
化合物# | 类型 | 小鼠输精管ED50(nM) | 豚鼠回肠ED50(nM | |
μ | δ | μ | ||
1 | 外消旋混合物DPI-1197W92(RRS和SSR) | 881 | 30 | 5.5 |
2 | 对映异构体DPI-125(SSR) | 38.8 | 14.2 | |
3 | 对映异构体DPI-165(RRS) | >1000 | >1000 | |
4 | 外消旋混合物DPI-1198W92(RSR和SRS) | 170 | 58 | 2.3 |
5 | 对映异构体ARD-444(RSR) | 79.3 | 1.3 | |
6 | 对映异构体DPI-3553W92(SRS) | >1000 | 282 | 365 |
化合物 | 类型 | 呼吸抑制ED50mg/kg | 止痛作用ED50mg/kg | 安全比 |
1 | 外消旋混合物DPI-1197W92(RRS和SSR) | 0.98 | 0.21 | 4.7 |
2 | 对映异构体DPI-125(SSR) | 0.72 | 0.046 | 15.7 |
3 | 对映异构体DPI-165(RRS) | >6.0 | >6.0 | 不确定 |
4 | 外消旋混合物DPI-1198W92(RSR和SRS) | 0.12 | 0.05 | 2.4 |
5 | 对映异构体ARD-444(RSR) | 0.067 | 0.03 | 2.2 |
6 | 对映异构体DPI-3553W92(SRS) | >6.0 | >6.0 | 不确定 |
附图 | 化合物 | 呼吸抑制在0.30mg/kg的基线pCO2单位% | 在0.30mg/kg的止痛作用(尾夹挤的延迟反应)(单位:秒) | ||||
4min | 8min | 32min | 4min | 8min | 32min | ||
图1 | 化合物1外消旋混合物DPI-1197W92(RRS和SSR) | 21% | 25% | 7% | 19.5 | 10.5 | 1 |
图2 | 化合物2对映异构体DPI-125(SSR) | 48% | 34% | 17% | 20 | 20 | 12.3 |
图3 | 化合物3对映异构体DPI-165(RRS) | 0 | 0 | 0 | 0 | 0 | 0 |
图4 | 化合物4外消旋混合物DPI-1198W92(RSR和SRS) | 117% | 91% | 43% | 20 | 20 | 10 |
图5 | 化合物5对映异构体ARD-444(RSR) | 120% | 78% | 45% | 20 | 20 | 20 |
图6 | 化合物6对映异构体DPI-3553W92(SRS) | 0 | 0 | 0 | 0 | 0 | 0 |
Claims (19)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32471201P | 2001-09-25 | 2001-09-25 | |
US60/324,712 | 2001-09-25 | ||
PCT/US2002/030398 WO2003026660A1 (en) | 2001-09-25 | 2002-09-25 | An enantiomerically pure diarylmethylpiperazine and methods of using same |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1558765A true CN1558765A (zh) | 2004-12-29 |
CN1558765B CN1558765B (zh) | 2012-01-04 |
Family
ID=23264757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN028187806A Expired - Fee Related CN1558765B (zh) | 2001-09-25 | 2002-09-25 | 对映异构体纯的阿片样物质二芳基甲基哌嗪及其使用方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US6924288B2 (zh) |
EP (1) | EP1438051A4 (zh) |
JP (1) | JP2005505575A (zh) |
KR (1) | KR20040041171A (zh) |
CN (1) | CN1558765B (zh) |
AU (1) | AU2002341832B2 (zh) |
BR (1) | BR0212742A (zh) |
CA (1) | CA2459577C (zh) |
IL (2) | IL160794A0 (zh) |
MX (1) | MXPA04002813A (zh) |
NO (1) | NO325958B1 (zh) |
NZ (1) | NZ531875A (zh) |
PL (1) | PL370346A1 (zh) |
RU (1) | RU2309153C2 (zh) |
WO (1) | WO2003026660A1 (zh) |
ZA (1) | ZA200402325B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105646332A (zh) * | 2014-11-09 | 2016-06-08 | 复旦大学 | 氨基甲基哌啶类衍生物及其制备方法和药物用途 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7189725B2 (en) * | 2001-09-25 | 2007-03-13 | Mount Cook Biosciences, Inc. | Enantiomerically pure opioid diarylmethylpiperazine as a cardioprotection agent |
US7314880B2 (en) * | 2003-01-02 | 2008-01-01 | Mount Cook Biosciences, Inc. | Cardioprotective delta opioid receptor agonists and methods of using same |
CN101198330A (zh) * | 2005-04-14 | 2008-06-11 | 蒙特库克生物科学公司 | 新阿片类化合物的组合物及其使用方法 |
US20070197786A1 (en) * | 2005-07-22 | 2007-08-23 | Kwen-Jen Chang | Enantiomerically pure opioid diarylmethylpiperazine |
KR101319390B1 (ko) * | 2007-04-25 | 2013-10-17 | 엘지전자 주식회사 | 대중 교통 정보를 제공하고 이를 이용하는 방법 및 장치 |
US11246865B2 (en) | 2017-04-30 | 2022-02-15 | Versi Group, Llc | Opioid for use to reduce and/or treat drug addiction |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020052007A1 (en) | 1992-02-03 | 2002-05-02 | Chang Kwen Jen | Diarylmethylbenzylpiperazines and corresponding halobenzyl derivatives |
GB9202238D0 (en) * | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
US5985880A (en) * | 1996-06-05 | 1999-11-16 | Delta Pharmaceuticals | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
US5807858A (en) | 1996-06-05 | 1998-09-15 | Delta Pharmaceutical, Inc. | Compositions and methods for reducing respiratory depression |
-
2002
- 2002-09-25 IL IL16079402A patent/IL160794A0/xx unknown
- 2002-09-25 CN CN028187806A patent/CN1558765B/zh not_active Expired - Fee Related
- 2002-09-25 KR KR10-2004-7004162A patent/KR20040041171A/ko not_active Application Discontinuation
- 2002-09-25 PL PL02370346A patent/PL370346A1/xx unknown
- 2002-09-25 BR BR0212742-3A patent/BR0212742A/pt not_active IP Right Cessation
- 2002-09-25 RU RU2004107850/15A patent/RU2309153C2/ru not_active IP Right Cessation
- 2002-09-25 NZ NZ531875A patent/NZ531875A/en not_active IP Right Cessation
- 2002-09-25 EP EP02775985A patent/EP1438051A4/en not_active Withdrawn
- 2002-09-25 CA CA2459577A patent/CA2459577C/en not_active Expired - Fee Related
- 2002-09-25 MX MXPA04002813A patent/MXPA04002813A/es active IP Right Grant
- 2002-09-25 AU AU2002341832A patent/AU2002341832B2/en not_active Ceased
- 2002-09-25 JP JP2003530295A patent/JP2005505575A/ja active Pending
- 2002-09-25 US US10/254,609 patent/US6924288B2/en not_active Expired - Lifetime
- 2002-09-25 WO PCT/US2002/030398 patent/WO2003026660A1/en active Application Filing
-
2004
- 2004-03-09 IL IL160794A patent/IL160794A/en not_active IP Right Cessation
- 2004-03-24 ZA ZA200402325A patent/ZA200402325B/en unknown
- 2004-04-23 NO NO20041729A patent/NO325958B1/no not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105646332A (zh) * | 2014-11-09 | 2016-06-08 | 复旦大学 | 氨基甲基哌啶类衍生物及其制备方法和药物用途 |
CN105646332B (zh) * | 2014-11-09 | 2018-05-25 | 复旦大学 | 氨基甲基哌啶类衍生物及其制备方法和药物用途 |
Also Published As
Publication number | Publication date |
---|---|
RU2309153C2 (ru) | 2007-10-27 |
IL160794A (en) | 2012-08-30 |
WO2003026660A1 (en) | 2003-04-03 |
CN1558765B (zh) | 2012-01-04 |
EP1438051A1 (en) | 2004-07-21 |
MXPA04002813A (es) | 2005-06-06 |
EP1438051A4 (en) | 2005-01-05 |
CA2459577C (en) | 2012-01-24 |
ZA200402325B (en) | 2005-01-13 |
NO20041729L (no) | 2004-06-25 |
JP2005505575A (ja) | 2005-02-24 |
BR0212742A (pt) | 2004-10-05 |
NZ531875A (en) | 2006-10-27 |
AU2002341832B2 (en) | 2008-10-30 |
NO325958B1 (no) | 2008-08-25 |
US20030114462A1 (en) | 2003-06-19 |
US6924288B2 (en) | 2005-08-02 |
KR20040041171A (ko) | 2004-05-14 |
CA2459577A1 (en) | 2003-04-03 |
RU2004107850A (ru) | 2005-04-20 |
PL370346A1 (en) | 2005-05-16 |
IL160794A0 (en) | 2004-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6919350B2 (en) | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds | |
KR101754045B1 (ko) | 항코넥신제로서의 플레카이니드의 용도 및 향정신 약물 효과를 증강시키는 방법 | |
CN1060775C (zh) | 用作神经递质重摄取抑制剂的稠合莨菪烷衍生物 | |
KR20070097590A (ko) | 치환된 아릴아민 화합물 및 5―ht6 조절제로서의 이의용도 | |
KR20110081839A (ko) | Gaba 접합체 및 그의 사용 방법 | |
JP2021120379A (ja) | 睡眠障害の治療及び予防 | |
RU2006139053A (ru) | Хинолинонкарбоксамидные соединения в качестве агонистов 5-ht4 рецепторов | |
CN1902215A (zh) | 甲硫氨酸氨肽酶-2的抑制剂及其用途 | |
CN1929829A (zh) | 作为d3激动剂的(s)-2-n-丙基氨基-5-羟基四氢化萘 | |
CN1427720A (zh) | 用于治疗耐受性和依赖性的促代谢谷氨酸受体拮抗剂 | |
US10251937B2 (en) | Retro-inverso analogs of spadin display increased antidepressant effects | |
CN1558765A (zh) | 对映异构体纯的阿片样物质二芳基甲基哌嗪及其使用方法 | |
CN1294576A (zh) | Vla-4拮抗剂 | |
CN1430597A (zh) | 新颖的mmp-2/mmp-9抑制剂 | |
US20200345726A1 (en) | Sleep disorder treatment and prevention | |
AU2002341832A1 (en) | An enantiomerically pure diarylmethylpiperazine and methods of using same | |
TW201118070A (en) | Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity | |
US7189725B2 (en) | Enantiomerically pure opioid diarylmethylpiperazine as a cardioprotection agent | |
CN1328548A (zh) | 作为凝血酶抑制剂的苯甲酰胺衍生物 | |
US11014933B2 (en) | Non-peptide opioid receptor modulators | |
US20070197786A1 (en) | Enantiomerically pure opioid diarylmethylpiperazine | |
TWI254638B (en) | An enantiomerically pure opioid diarylmethylpiperazine and methods of using same | |
CN1697657A (zh) | 保护心脏的δ类阿片受体激动剂和使用该激动剂的方法 | |
MXPA00000195A (en) | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: VERMONT COOK BIOLOGICAL SCIENCE CO., LTD. Free format text: FORMER OWNER: ARDENT PHARMACEUTICALS INC. Effective date: 20071102 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20071102 Address after: American New York Applicant after: MOUNT COOK BIOSCIENCES, Inc. Address before: North Carolina Applicant before: ARDENT PHARMACEUTICALS, Inc. |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20041229 |
|
CI01 | Publication of corrected invention patent application |
Correction item: Rejection of patent application Correct: Dismiss False: Reject Number: 32 Volume: 26 |
|
ERR | Gazette correction |
Free format text: CORRECT: PATENT APPLICATION REJECTION AFTER PUBLICATION; FROM: REJECTION TO: REJECTION OF REVOCATION |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WYLCI IBRAHIM Free format text: FORMER OWNER: MT. COOK PHARMA, INC. Effective date: 20120319 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: MT. COOK PHARMA, INC. Free format text: FORMER NAME: MOUNT COOK BIOSCIENCES INC. |
|
CP01 | Change in the name or title of a patent holder |
Address after: American New York Patentee after: MT. Cook pharmaceuticals Address before: American New York Patentee before: MOUNT COOK BIOSCIENCES, Inc. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120319 Address after: New jersey, USA Patentee after: Ibrahim Velsi Address before: American New York Patentee before: MT. Cook pharmaceuticals |
|
ASS | Succession or assignment of patent right |
Owner name: WEIERXI GROUP CO., LTD. Free format text: FORMER OWNER: WYLCI IBRAHIM Effective date: 20131119 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20131119 Address after: New jersey, USA Patentee after: Wersi Refco Group Ltd. Address before: New jersey, USA Patentee before: Ibrahim Velsi |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120104 Termination date: 20190925 |
|
CF01 | Termination of patent right due to non-payment of annual fee |